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ABSTRACT

PURPOSE: The aim of the current study was to determine if decomposition quantitative
electromyography (DQEMG) reflected the clinical presentation of patients with muscular
dystrophy (MD). The clinical measure which best predicted functional ability was also
investigated. METHODS: Fifteen patients with fascioscapulohumeral (FSHD), limbgirdle (LGMD), and Beckers (BMD) muscular dystrophy and seven healthy controls
participated in the study. Isometric strength and isotonic power of the right leg were
assessed with a Biodex dynamometer. Functional ability was determined by performance
on stair climb, chair rise, and gait velocity tasks. The vastus lateralis, biceps brachii, and
tibialis anterior muscle groups of the right side were investigated using DQEMG. The
following motor unit potential (MUP) parameters were analyzed and compared with
control data: duration, amplitude, area, area-amplitude ratio, and number of phases and
turns. MRI was used to evaluate right side quadriceps muscle volume. RESULTS:
Patients with MD had reduced quadriceps strength, power, muscle volume and functional
ability compared with controls. Maximum voluntary contraction (MVC) force was
determined to correlate most strongly with patient’s functional ability. MUP duration was
found to indicate the severity of the myopathy and correlated significantly with
quadriceps strength, power, and muscle volume in patients with MD. CONCLUSION:
DQEMG reflects the underlying pathology of the myopathy, which manifests clinically as
weakness and compromised functional ability. Furthermore, the functional ability of
patients with MD is strongly predicated by MVC strength.
Keywords: Myopathy, Muscular Dystrophy, DQEMG, isotonic power, strength,
functional ability, MRI
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CHAPTER 1
CLINICAL PRESENTATION AND ASSESSMENT OF MUSCULAR
DYSTROPHY

1.0 GENERAL INTRODUCTION
1.0. 1 Muscular Dystrophy
The muscular dystrophies (MD) refer to a group of hereditary disorders
characterized by progressive muscle weakness and atrophy39'21. MD manifests from
mutations in genes that code for proteins including those involved in maintaining the
structural integrity of muscle fibers. Defects in the structural proteins may cause muscle
fiber membrane instability resulting in muscle fiber degeneration and necrosis.
Eventually, the rate of degeneration exceeds the regenerative capacity of the muscle
fibers leading to the replacement of muscle by fat and connective tissue .
MDs that share similar clinical phenotypes are usually grouped together. Although
these groups may be clinically homogeneous, different genetic forms within each group
may exist. This paper will focus on the limb girdle (LGMD), facioscapulohumeral
(FSHD), and Becker (BMD) muscular dystrophies. These MDs were selected for review
as there is overlap in muscle group involvement. However, these MDs have distinctly
different underlying pathophysiological mechanisms causing muscle fiber degeneration
and subsequent muscle weakness, as well as differing modes of inheritance.
1.0. 2 Clinical Aspects of Muscular Dystrophy
FSHD is the third most common inherited muscular dystrophy55. Prevalence is
roughly 50 per million and incidence is about 4 per million3. Approximately 30% of
affected family members are unaware of their deficits. Disease onset is usually before age
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10, however many patients do not acknowledge symptoms until the second to third
decade of life46,56. Although FSHD progression has a distinct and uniform pattern, there is
large variability in the rate and extent of progression amongst individuals, even amongst
family members. FSHD is an autosomal dominant muscular dystrophy46. Although
prevalence of FSHD is similar in males and females, there appears to be a gender-specific
influence on the degree and rate of disease progression in FSHD41. Symptoms of FSHD
in females tend to present later in life and in a milder form. This gender difference is
currently not well explained, however it has been hypothesized that it is due to the
protective nature of certain female hormones56.
FSHD is characterized by weakness and wasting of the muscles of facial
expression and of the shoulder girdle3. Although facial muscles are typically the first to
be involved, many patients are unaware of their weakness. Patients usually do not
appreciate the onset of symptoms until they experience difficulty abducting their arms,
which may not occur until many years after facial weakness manifests55. The primary
muscles involved in the shoulder girdle are the latissimus dorsi, serratus anterior,
rhomboids, inferior part of the trapezius, and the pectorals46. Weakness in these muscles
can also result in scapular winging. Following involvement of the shoulder girdle,
weakness is likely to spread down the arm to simultaneously involve the biceps, triceps
and brachioradialis46. The pelvic girdle and upper leg muscles reflect the last muscle
groups to become involved3. It is not uncommon however, that the peroneal and tibialis
anterior muscle groups may become involved before the pelvic girdle46,41. Weakness and
atrophy in the aforementioned muscles leads to foot-drop and can make running nearly
impossible3. FSHD commonly manifests with striking asymmetry of muscle
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involvement3,46. Many individuals with FSHD remain ambulatory throughout life, while
approximately 20% eventually require a wheelchair46. Life span is usually normal41.
Limb girdle muscular dystrophy refers to a heterogeneous group of MDs that
present with weakness involving the shoulder and hip girdle musculature. There are many
subtypes of LGMD that differ in age at onset, severity, and mode of inheritance .
Prevalence rate of LGMD ranges from 8 to 70 per million3, and there is equal occurrence
in males and females. Inheritance of LGMD is either autosomal dominant or recessive in
nature31. Dominantly inherited variants are designated as LGMD 1 and autosomal
recessive subgroups are termed as LGMD 2. There are 7 known dominant subgroups and
13 known recessive subgroups21, each of which are assigned an alphabetical
subclassification to indicate they are genotypically distinct. The majority of LGMD cases
tend to be autosomal recessive in etiology, while autosomal dominant forms are found in
only a few families15.
There is significant overlap in the clinical presentations of the various types of
LGMDs. Onset of weakness can range from early childhood to late adulthood, and the
11

.

degree of involvement can range from severe to mild . Weakness and wasting first
become apparent in either the shoulder girdle region (trapezius and pectoralis muscle
groups), or the pelvic girdle region (gluteus and adductor muscle groups), or both regions
simultaneously21. Individuals with the recessive form of LGMD may also have early
involvement of the gastrocnemius, soleus, and tibialis anterior muscle groups. Over time,
the biceps, brachioradialis and the quadriceps become involved31. Facial, extraocular, and
pharyngeal muscles are usually spared. Rate of progression is steady, but variable
amongst individuals. Patients with pelvic-girdle weakness commonly experience
difficulty rising out of chairs and climbing stairs. Weakness of the shoulder-girdle
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muscles leads to difficulty in reaching for objects above shoulder height. Approximately
50% of patients are non-ambulatory by the age of 20 years, but many are able to walk late
in life3.
Becker MD represents a similar clinical picture to the more commonly known
Duchenne muscular dystrophy (DMD), however it is less severe and has a slower rate of
progression . BMD is an X-linked recessive disorder with approximately 10% of cases
resulting from spontaneous mutations3. Incidence is approximately 5 per 100 000
individuals3. Onset of symptoms usually occurs between the ages of 5 and 15 years, but
occasionally symptoms do not manifest until the third or fourth decade. Clinical features
of BMD include ambulation maintained past the age of 15, a limb-girdle pattern of
muscle weakness, and calf pseudohypertrophy3. By the fourth decade, about half of
affected individuals have lost the ability to ambulate independently. Cardiac
abnormalities including dysrhythmias are not uncommon, and congestive heart failure can
occur late in the disease. Life expectancy may be reduced in patients with BMD, but most
patients survive into the fourth or fifth decade.
1.0.3 Pathophysiology of Muscular Dystrophy
Muscular dystrophy, in the most general terms, is an imbalance between muscle
fiber degeneration and regeneration. The muscle plasma membrane, or sarcolemma, is a
highly organized and specialized cellular structure designed to withstand the stresses
associated with repeated cycles of muscle contraction and relaxation . In MD, the muscle
fiber’s susceptibility to injury is increased due to defects in proteins involved in
maintaining the structural integrity of the muscle fiber membrane. When skeletal muscle
is injured, unique stem cells, termed satellite cells, are responsible for the regenerative
potential of the cell24. Satellite cells are found beneath the basal lamina and are in direct
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contact with the sarcolemma. Following damage, satellite cells emerge from a state of
arrest and reenter the mitotic cycle29. The newly formed myoblasts are capable of fusing
with injured fibers or forming new fibers in a process termed myogenesis24. Early in the
disease, degeneration and regeneration processes dominate, but eventually the
regenerative capacity of the muscle fiber is reached and degenerated muscle cannot be
repaired. At this point, necrotic muscle cells are replaced with fatty and fibrous tissue.
The dystrophin-glycoprotein complex (DCG) plays an important role in
stabilizing the sarcolemma by linking the cytoskeleton to the extracellular matrix
(ECM)35. In healthy skeletal muscle, dystrophin, located at the cytoplasmic face of the
sarcolemma, links the intracellular actin network to the sarcolemma31'35. At the
sarcolemma, dystrophin associates with the transmembrane protein (3-dystroglycan which
is connected to the highly glycosylated a-dystroglycan15. a-Dystroglycan completes the
cytoskeletal-ECM link as it binds in a calcium-dependent manner to extracellular proteins
such as laminin1529'35 (Figure 1.1). A disruption in the link by a deficiency in any of these
proteins leads to muscular dystrophy .
Dystrophin is the gene product deficient in both DMD and BMD3. These disorders
are collectively termed the dystrophinopathies. In DMD, the dystrophin protein fails to be
produced, whereas in BMD the protein is present, but abnormal16. Abnormal quality or
quantity of dystrophin results in muscle losing its ability to maintain its integrity during
contraction, leading to membrane disruption and subsequent muscle fiber necrosis16.
Muscular dystrophies also arise due to inadequate glycosylation of adystroglycan. The protein must be glycosylated during post-translation modifications in
order to function properly and link the DCG with the ECM. Mutations in fukutin-related
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protein (FKRP) disrupt the glycosylation of a-dystroglycan ’ . This results in a spectrum
of MD phenotypes ranging from severe congenital MD to the less severe and later onset
LGMD2I6. As well, in some cases of LGMD2I, abnormalities in laminin-a2, an extra
cellular protein involved in linking the DCG to the basal lamina, have been recognized29.
The a, (f, y, and 5 sarcoglycans are transmembrane glycoproteins which form a
distinct sub-complex of the DCG29 (Figure 1.1). The function of the sarcoglycans remains
to be fully elucidated, however it is suggested that the primary function of this protein
complex is to stabilize the a-(3 dystroglycan interaction . Thus, by stabilizing
components of the DCG, the sarcoglycans help to maintain muscle membrane integrity by
providing mechanical reinforcement during the contraction-relaxation cycle. Deficiencies
in the sarcoglycans are associated with autosomal recessive forms of LGMD (LGMD2CF), which are collectively known as the sarcoglycanopathies29. A deficiency in any one of
the proteins involved in the sarcoglycan complex typically results in a loss of the other
members of the protein complex from the sarcolemma29'31.

7

Mer Osin-deficient
CMD

Basal lamina
_Clycosyltransferase

FKRP(LGMD2I)

LGMD 1C

.a « »

Caveol in-3
Syntrophins
DMD/BMD

Mathews, K.D., & Moore, S.A. 200331

Figure 1.1 Representation of the dystrophin-glycoprotein complex and other sarcolemmal
proteins relevant to muscular dystrophy. The DGC at the sarcolemma links the ECM to
the actin cytoskeleton. The sarcoglycans form a distinct subcomplex to the DCG. MD
types are indicated with their associated protein. With kind permission from Springer
Science+Business Media: Curr Neurol Neurosci Rep, Limb-girdle muscular dystrophy, 3,
2003, page 80, Mathews KD, Moore SA, Figure 1.
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Although much of the pathology of MD can be explained by the loss of the
cytoskeletal-extracellular matrix linkage, not all types of MD have this underlying
pathophysiological mechanism. Defects in calpain-3, a proteolytic enzyme, have been
shown to cause a relatively common form of LGMD, LGMD2A15’31. This muscle
specific, calcium dependent protease appears in both the cytosol and the nucleus. This
leads to the suggestion that it may have a role in the regulation of muscle cell
differentiation by controlling the level of muscle-specific transcription factors . It has
also been suggested that deficiencies in calpain-3 disrupt protein interactions at the
sarcolemma and/or Z-line of the sarcomere29, as calpain-3 interacts with titin15. It is
unknown whether these are truly the functions of calpain-3 in muscle, and the exact
mechanism which calpain-3 deficiencies cause MD still remains to be fully elucidated15.
The pathophysiological mechanism responsible for muscle weakness in FSHD is
currently unknown. Although the genetic lesion in FSHD has been identified (partial
deletion of repetitive elements on chromosome 4q35), the protein product(s) have yet to
be determined55. It has been shown that there is significant modification of the
sarcolemma in FSHD, observed in both ultrastructural and immunofluorescence studies45.
It is hypothesized that the observed increased gap size between the sarcolemma and the
nearby myofibrils, compared with controls, reduces the efficiency with which contractile
force is transmitted across the cell membrane to the ECM, ultimately causing muscle
weakness45. The increased sarcolemma-to-myofibril gap is also speculated to induce cell
damage as it causes increased movement of cytoplasmic material between the myofibrils
and the sarcolemma during contractions. Further shear-induced damage is thought to
rupture the plasma membrane, ultimately leading to loss of myofibers45.
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1.0.4 Electrophysiologic Assessment of Myopathies
Intramuscular needle electromyography (EMG) has played an important role
aiding in the diagnosis and characterization of neuromuscular diseases for more than 50
years43. EMG records trains of discrete waves called motor unit potentials (MUPs). The
MUP, recorded with an intramuscular needle electrode, is the compound of the
extracellularly recorded action potentials of all the muscle fibers within the motor unit
(MU)14,12. The MU is the basic component of the peripheral nervous system and is
defined as one alpha motor neuron and all the muscle fibers it innervates. The area in
which muscle fibers belonging to one MU are distributed is called the motor unit
territory. In the biceps brachii and the tibialis anterior muscles the motor unit territory has
a cross-sectional area with a diameter of 5-10 mm12. Motor unit territories of individual
MUs overlap and thus muscle fibers from a single MU are intermingled with fibers from
other MUs. This makes it possible for an electrode to record MUPs from multiple MUs
during a single contraction.
In healthy skeletal muscle, the extracellularly recorded MUP is triphasic. The
initial positive deflection is generated by the action potentials propagating toward the
electrode38. The positive, or downward deflection corresponds to the advancing current
source of outward current that depolarizes the next section of membrane to initiate the
action potential52. The negative peak corresponds to the inward-directed current where an
action potential is in progress. The final positive segment forms as the repolarizing
outward current source moves away from the electrode . If the electrode is placed near
the end plate region, the initial positive deflection will not be recorded. The potential will
have a biphasic waveform with an initial negative deflection38'52.
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The extracellular waveform also depends on the placement of the electrode
relative to the muscle fiber. A potential recorded a short distance from the muscle fiber
has a short rise time and high amplitude. A short distance potential is described as
sounding “crisp” and “sharp”. If the distance between the electrode and muscle fiber is
greater, then the potential recorded has a low amplitude with a long rise time and sounds
“dull”38.
Analyzing MUPs collected by intramuscular EMG provides valuable information
regarding the physiological status of the muscle being investigated. The shape of the
MUP waveform is dependant on the architecture of the MU (the number, size, and
distribution of fibers and end plate zone) and is remodeled as a result of disease
processes. From the observed morphological changes in MUPs, conclusions regarding
type of disease (myopathic, neurogenic) can be made. Motor unit architecture changes in
myopathies are due to multiple factors such as loss, hypertrophy, atrophy, and
regeneration of muscle fibers37,17. It is important to note that while EMG can separate
myopathic from neuropathic disease, it is unable to differentiate a specific neuromuscular
diagnosis13. At least 20 MUPs should be collected for analysis when attempting to
characterize muscle as myopathic, neuropathic, or normal. As well, it should be ensured
that recording sites are at least 10 to 20 mm apart to avoid multiple recordings of the
same MUP8. MUP duration, amplitude, area, thickness, turns, phases, and satellite
potentials are the common parameters assessed when investigating MUP morphology.
Buchthal et al. 10,14 distinguished between specific and non-specific features of the MUP
waveform. A specific feature is considered a morphological characteristic confined to a
myogenic or neurogenic lesion, where nonspecific criteria can occur in both lesion types.
MUP duration is traditionally considered the most robust MUP feature, as it is less
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dependent than amplitude on the needle electrode position within the motor unit
territory38. Duration is measured as the time from the initial deflection of the MUP from
baseline to its final return to baseline (Figure 1.2). It is the parameter that best reflects the
number of muscle fibers in the motor unit and the dispersion of their depolarizations over
time. The MUP duration is characteristically decreased in myopathic muscle and is a
specific feature ’ ’ ’ . This is best explained by a random loss of muscle fibers from
MUs14'50. As muscle fibers are randomly lost as a result of necrosis, the periphery of the
MU is eliminated and therefore the temporal dispersion of the surviving fibers is
diminished14.
Amplitude is measured from the maximum negative to maximum positive peak
(Figure 1.2). Amplitude is most affected by the location and diameter of the muscle fiber
nearest the electrode36. The amplitude of the concentric-needle MUP is highly dependent
on the position of the needle detection surface relative to the muscle fibers of a given
MU. Thus, it reflects only the contribution of a small number of muscle fibers closest to
the needle tip36. As a consequence, mean amplitude is deemed not very useful in terms of
differentiating myopathies27. It is typically reported however, that individual MUP
amplitude is reduced in myopathic muscle, which is considered a non-specific
feature2223,53. This is probably a result of muscle atrophy and loss of the number of
contributing muscle fibers to the MUP. In acute and intermediate stage myopathies
increased amplitude has been observed. This may be due to the presence of hypertrophic
muscle fibers and the variable muscle fiber diameter during the regeneration phase of the
disease.
The MUP area is measured by integrating the rectified signal waveform over its
duration (Figure 1.2). The area reflects the number and diameter of muscle fibers and the
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temporal distribution of the individual muscle fiber action potentials. MUP area is
generally reduced in myopathic muscle.
Nandedkar et al.36 introduced the area/amplitude ratio (AAR), or “thickness”, as a
means to normalize the marked differences in MUP amplitude observed with even slight
changes in the position of the recording electrode. Thickness is much less affected by
changes in electrode position and may be more sensitive to changes in myopathic muscle.
Even when MUP amplitude was normal or increased, AAR was reduced, a feature more
representative to the physiological changes in myopathic muscle fibers.
Polyphasia is considered a non-specific criterion of myopathy and neuropathy.
The number of phases is defined as the number of baseline crossings plus one (Figure
1.2). In order for a MUP to be considered polyphasic, 5 or more phases must be observed.
In myopathy, if the dispersion of muscle fibers belonging to one MU is more than 1-2 ms.
the summation of the muscle fibers in the MU will result in a MUP consisting of more
than 4 phases58. Polyphasic potentials result from a loss of muscle fibers, regeneration of
muscle fibers13, or variation in muscle fiber diameter50. Short polyphasic potentials are
due to fiber loss where polyphasic potentials of long duration are attributable to slowed
conduction along regenerating muscle fibers14.
The number of turns reflects properties of the MU that are similar to that which
results in the number of phases. The number of turns is defined as the number of positive
and negative peaks separated by a certain amplitude differential, usually 20 or 50 pV.
(Figure 1.2). It has been suggested that this parameter is more sensitive than phases at
highlighting the structural changes that occur in muscle fibers as a result of
neuromuscular lesions50.
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Figure 1.2
Representation of a typical MUP waveform. The sum of the positive and negative
peak areas is defined as the total MUP area. Turns are indicated by arrows and phases are
indicated by dots. Reprinted from Med Eng Phys, Vol. 21, Pattichis CS, Elia AG,
Autoregressive and cepstral analyses of motor unit action potentials, Pages 405-419,
1999, with kind permission from Elsevier.

Finally, intramuscular EMG can be used to investigate recruitment pattern. There
are two mechanisms by which skeletal muscle can increase force production; MUs can
increase their firing rate, until tetanic frequency is achieved (approximately at 30Hz), or
by increasing the number of MUs recruited. Individual muscle groups use a variable
combination of both of these mechanisms to obtain and control force output, resulting in
an orderly recruitment of motor units. In myopathies, early recruitment is observed. This
is considered a non-specific criterion of myopathies. Early recruitment refers to an
increased number of MUs firing in order to achieve a certain absolute force. Hence, for
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the same force output, more MUPs will be observed in myopathies compared with
healthy muscle. It is suggested that this phenomenon is due to the dropout of individual
muscle fibers from the motor unit. The motor unit becomes smaller and subsequently can
generate less force. As each motor unit generates less force, many motor units must fire to
generate a given force. In late stage of chronic myopathy, recruitment of MU is actually
reduced compared to healthy muscle. At this point in the disease process, so many muscle
fibers have become necrotic that the actual number of MUs has decreased. So in order to
produce even a small amount of force, many, if not all, available MUs must be recruited9.
A reduced recruitment pattern during full force is non-specific to myopathies.
MUP analysis can be accomplished by either qualitative or quantitative methods.
Qualitative assessment of MUP morphology is usually performed using auditory and
visual information obtained from an oscilloscope and loudspeaker. As MUPs are
interpreted subjectively, this method is inherent to bias. It has also been suggested that
this method may not be reliable when investigating neuromuscular disorders at their early
and intermediate stages as small, but important, changes in MUP morphology may be
undetected27.
In the mid-1950s, Buchthal and colleagues11introduced a method for quantitative
EMG (QEMG) analysis that allowed for a more objective, reproducible, and
diagnostically sensitive analysis of MUPs from which pathological features of affected
muscles can be characterized. As well, this method made it possible to provide baseline
values against which future studies can be compared and to monitor the effectiveness of
treatment interventions over time20. However, the method involved manually collecting
individual MUPs, one by one from a storage oscilloscope, and measuring their features
off-line which was too time consuming for routine clinical practice. Additionally, due to
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the inability of this method to decompose signals from a complex interference pattern,
sampling was limited to examining the small population of low-threshold MUPs. As the
order of MUP recruitment in muscle is fixed30, MUPs with higher recruitment threshold
are not investigated with this method. Based on these limitations, this manual or Buchthal
method of quantitative MUP analysis was seldom used clinically.
As technology advanced, new computerized methods for automatic QEMG
analysis were introduced ’ ’ . These techniques made it possible for MUPs to be
sampled at higher percentages of maximum voluntary contractions (MVC), provided a
more objective means of analysis, and allowed for faster QEMG analysis. Many of these
techniques rely on decomposing the EMG signal into its constituent MUP trains32,33. The
resulting MUP trains represent the activity of the active MUs firing within the recording
region of the intramuscular electrode. Morphological features of the collected MUPs, as
well as recruitment patterns, are then possible to analyze.
Recently, Stashuk and colleagues developed a system of computer-based
algorithms for EMG signal decomposition and quantitative analysis (DQEMG)51.
DQEMG decomposes, or breaks down, the EMG signal by using shape and temporal
information related to the individual MUP discharges in addition to MU firing time
statistics. A series of automated steps classifies individual MUPs which are then assigned
to their appropriate group and ultimately, to their individual MUP trains. Once the EMG
signal is acquired, individual MUPs that make up the signal must be clustered into groups
of responses of similar shape. MUPs are clustered into groups, each with a prototypical
shape, based on pattern recognition algorithms. The algorithm is based on morphological
statistics such as peak-to-peak voltage, number of phases, duration and slope. Using the
clustering results, a supervised classification algorithm combines shape and firing time
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statistics to calculate the certainty with which the individual MUP assignments have been
made. A prototypical MUP shape is then estimated for each MUP train19,51. DQEMG thus
is able to provide clinically useful information pertaining to the physiological status of the
MU by the analysis of the individual needle-detected MUPs.
In addition to providing quantitative data in the form of needle-detected MUPs,
DQEMG has the advantages of timely data acquisition and processing, as well as the
ability to obtain MUPs from MUs with low and higher recruitment thresolds4,19. It is also
advantageous in that operator bias is removed since the sample of MUPs is extracted from
the interference pattern based on consistent algorithmic criteria. This method has been
shown to be clinically applicable19 and normative data has been reported19,4. However,
this technique has yet to be validated in myopathic populations.
1.0.5 Strength, Power, and Functional Ability in Muscular Dystrophy
The muscular dystrophies are chronic diseases characterized by progressive
muscle weakness. Currently there is no cure and little in the way of treatment for
muscular dystrophy, so disease management is mainly supportive in terms of the patient’s
progressive weakness and functional decline. Manual muscle testing (MMT) and
quantitative muscle testing (QMT) are most commonly used clinically to evaluate and
summarize muscle strength. MMT is an established, reliable method for monitoring
strength in neuromuscular disease25. The Medical Research Council Scale (MRC) for
MMT grades muscle strength on an ordinal scale from 0 to 5, with 0 representing absence
of any perceptible movement and 5 indicating normal strength. A muscle rated grade 3 is
able overcome gravity, but not resistance25. A limitation of this system is that Grade 4
strength represents a very broad spectrum ranging from the first clear evidence of
weakness through slightly better than anti-gravity strength (ie Grade 3). Therefore, this
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grade is often subdivided to 4-, 4, 4+ to indicate whether the muscle strength correlated
with slight, moderate, or strong resistance, respectively7. QMT directly measures force
production through the use of a dynamometer. A dynamometer is a force transducer that
converts ‘muscle strength’ into newtons, thus providing a true unit of measure47. This
method to measure muscle force has been shown to be reliable in DMD patients on same
day test/re-test measurements48. MMT and QMT methods can both provide valuable
information about the presence and rate of progression of muscle weakness, and have the
potential to aid in the evaluation of possible treatment interventions. Both methods
however, possess their own advantages and limitations. QMT assessed by a dynamometer
provides quantitative continuous data, which removes some of the subjectivity and lack of
sensitivity associated with MMT. However, the clinical significance of quantitative
strength measurements may be less obvious than that of MMT, as it requires the use of a
dynamometer and may not be applicable as such to testing multiple muscle groups.
It has been reported that patients are more interested in their progressive
worsening, or loss of functional ability, than in weakness per se. Thus, many clinicians
and therapists feel the assessment of function is important when monitoring disease
progression. Muscle function and muscle strength are two fundamentally different
parameters of the motor system and thus, manifest differently47. Brooke et al.48 reported
that patients with DMD maintained their ability to perform functional tasks, such as
walking, over a period of a few years even while their muscle strength, measured by
MMT, declined over this period. Patients then experienced a period of rapid decline and
‘catastrophic’ loss of functional ability. Surprisingly, this period was not matched with
any acceleration in muscle weakness. These two phases of functional status in patients
with MD was also described by Allsop and Ziter2. This group commented further that a
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pattern of compensatory mechanisms were used by patients in order to achieve functional
goals as their muscle strength deteriorated.
Clinically, functional testing is useful to help to characterize the progression of
muscular dystrophy, as well as to indicate the appropriate time at which therapeutic
interventions of surgery and bracing may be most benificial7. There are limitations
however, associated with functional testing. There is the potential of assessor error in
timing with the commonly used stair climb, walk 10m, and ‘sit to standing from a chair’
tests. As well, performance on these timed tests can be affected by the patient’s mood,
level of motivation, and ability to cooperate.
Recently, studies have reported that muscle power may be more directly related to
functional limitations than muscle strength26,18,44. Muscle strength is defined as the
maximum force generating capacity of the muscle, while muscle power is characterized
by the product of force production and the velocity at which the force is produced44.
Many basic activities in daily life, such as walking, climbing stairs, or standing from a
seated position, are both force and speed dependant and thus, require leg muscle power .
The applicability of power measurements is task dependent. Power measurements, where
the load is high and velocity is low, are more representative of high-intensity activities
such as the stair climb and chair rise . Variability in function in lower intensity activities,
such as walking, are best explained during low force-high velocity power
1R

measurements ' .
MMT, QMT, functional, and power measurements all provide valuable
information pertaining to the functional ability and progression of weakness in
individuals with muscular dystrophy. Although these measures describe slightly different
mechanisms of the motor system, the information provided is complementary in nature.
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In the clinical setting, it would perhaps be most useful to use these measures in
combination in order to best describe the disease process.
1.0.6 MR I in the Assessment of Muscular Dystrophies
Recently, several studies have reported the value of muscle magnetic resonance
imaging (MRI) in the assessment of muscular dystrophies34,49,40. An advantage of MRI is
that muscle status can be investigated in vivo. Also, both quantitative and qualitative
analysis methods can be used to describe the degree of muscle degeneration and
subsequent infiltration of fatty and connective tissue1. Studies have found that the degree
of fatty infiltration is a sensitive indicator of disease progression in patients with muscular
dystrophy. Qualitative measures of fat infiltration correlated more strongly with
functional grade than MMT and muscle strength measured by a dynamometer did57.
Furthermore, MRI has been particularly valuable in identifying patterns of muscle
involvement in muscular dystrophies40,49. It has been reported that MRI is able to detect
evidence of muscle abnormality even before it manifests clinically49. Currently, few
studies have employed MRI to investigate muscular dystrophy. Furthermore, muscle
volume has not been evaluated quantitatively in this myopathic population. Thus, this
field has potential to provide new and influential information that may aid in the
diagnosis, understanding of the pattern and distribution of muscle involvement, and the
evaluation of therapeutic interventions in the different muscular dystrophies.
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CHAPTER 2
DQEMG IN THE EVALUATION OF MUSCULAR DYSTROPHY SEVERITY

2.0 INTRODUCTION
The muscular dystrophies (MD) can be defined as a group of genetic disorders
characterized by progressive muscle weakness and atrophy18. Muscle weakness manifests
as a result of the sarcolemma’s increased susceptibility to injury due to defects in proteins
involved in maintaining the integrity of the cytoskeletal-extracellular matrix linkage 15.
Although the Limb girdle (LGMD), Facioscapulohumeral (FSHD), and Becker (BMD)
muscular dystrophies have distinctly different underlying pathophysiological mechanisms
leading to muscle fiber degeneration, they present clinically with similar muscle group
involvement and rate of progression.
Electrophysiological evaluation is often a useful component of the diagnosis and
management of patients with myopathic disorders. Quantitative electromyography
(QEMG) can help characterize pathological features in neuromuscular disorders through
the assessment of needle-detected motor unit potentials (MUPs)19,17. It is well established
that although QEMG is useful in detecting myopathic changes in affected muscles, it is
unable to differentiate between different myopathies and determine specific diagnoses6. It
has been suggested however, that once a specific diagnosis is established by clinical,
biochemical, and molecular genetic test results, QEMG could provide information
regarding disease severity as MUP morphology reflects the architecture of the motor unit
(MU)24,23’10,11. If so, this technique could aid in determining prognosis and aid in the
investigation of effective therapeutic treatments.
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To date, there are few studies investigating the possible correlation between
changes in MUP morphology and disease severity in patients with MD. Recently,
Emeryk-Szajewska and Kopec11 evaluated the EMG pattern in slightly and severely
affected biceps brachii and rectus femoris muscle groups in 51 males with Duchenne
muscular dystrophy (DMD). They reported that the myopathic changes observed in the
needle-detected MUPs, collected using their own Function-QEMG method, were more
profound in more severely affected muscles. The same group performed a complementary
study comparing the MUPs of the patients with DMD to 14 males with BMD, again
employing their own Functional-EMG method to collect the data10. Differences in MUP
parameters were less obvious than in the aforementioned study, but still evident. Two
studies by Stubgen2423 also investigated whether QEMG is able to indicate disease
severity in patients with MD. Those studies aimed to determine whether changes in MUP
characteristics correlated with clinical features (strength assessed by MMT) and disease
duration of patients with FSHD and LGMD. Furthermore, the author was interested in
whether MUP characteristics of MD differed from those collected from a healthy, control
group. Results indicated that MUP characteristics significantly differed in patients with
FSHD and LGMD in comparison to controls. Also, MUP amplitude and duration of the
triceps brachii, and to a lesser extent tibialis anterior muscle groups were inversely
correlated to the duration of FSHD involvement. No direct correlation was found between
disease duration and MUP characteristics in the LGMD group. Overall, the results of
these studies suggest that changes in needle-detected MUPs may reflect the successive
stages of disease involvement in MDs. However, as MD severity was determined using
subjective measures, much remains to be learned regarding the utility of EMG in
assessing disease severity before accurate conclusions can be drawn.
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The purpose of the current study was to determine whether MUP parameters,
collected using decomposition-based QEMG (DQEMG), are related to clinical features of
patients with LGMD, FSHD, and BMD. Quantitative measures of isometric strength,
isotonic power, functional performance, and muscle volume assessed by MRI, served as
objective clinical measures and indicators of disease severity.
We hypothesized that MUP morphology would not only differ between control
subjects and patients with MD, but that DQEMG would also detect differences between
more and less severe myopathic conditions. In addition, this study aimed to determine if
isotonic power was better able to predict functional ability in patients with MD than
isometric strength. We hypothesized that power will predict functional ability to a greater
extent than isometric strength, since activities of daily living are dependent on both force
and speed production.
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2.1 METHODS

2.1.1 Subjects
Fifteen individuals, with a previously determined diagnosis of muscular dystrophy
participated in this study. In addition, a group of seven healthy subjects with no evidence
of neuromuscular or musculoskeletal disorders volunteered to act as control subjects.
Participants diagnosed with muscular dystrophy were recruited through the
Neuromuscular Clinic at University Hospital, London Health Sciences Centre, London,
Ontario. Diagnosis was confirmed by clinical assessment, muscle biopsy, and/or genetic
testing. Control subjects were recruited from the university community and considered to
be recreationally active.
The study protocol was approved by the University of Western Ontario’s ethics
review board and was conducted in accordance with its guidelines for experimentation on
human subjects and conformed to the Declaration of Helsinki. Informed, written consent
was obtained from all participants.
2.1.2 Muscle Function Analysis
For strength, power, EMG, and MRI studies, muscle groups in the right upper and
lower limb were investigated when patients presented with symmetrical muscle
involvement. For patients with asymmetric muscle involvement, the more affected side
was examined, unless less than antigravity strength was demonstrated during leg
extension. Right side muscle groups were examined in all control participants.
Strength and Power Experimental Set-up. A Biodex multijoint dynamometer (System 3,
Biodex Medical Systems, Shirley, New York) was used to assess muscle strength and
power. Participants were seated in the adjustable Biodex chair with their hip and knee
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angles at 90°. A goniometer was used to ensure accurate joint angles. The ankle was
secured to the dynamometer arm using Velcro straps around a padded ankle attachment.
An adjustable seat belt across the waist and shoulder straps were used to minimize hip
flexion and upper body movement.
Experimental Protocol. Three isometric maximal voluntary contractions (MVCs) of the
quadriceps were performed with 2 min of rest separating each attempt. Subjects held each
MVC for 3-5 s. Participants received visual feedback of torque via a computer screen.
Strong verbal encouragement was provided during the contractions in an attempt to obtain
the best possible performance.
To determine power, the dynamometer was then switched from the isometric to
isotonic mode. The range of motion (ROM) of the tested leg was set to 90° by instructing
the participant to fully extend the knee, then flex the knee until the dynamometer
indicated 90° ROM had been achieved. Each participant contracted against submaximal
loads of 10, 20, 30, 40 and 50% of their largest predetermined isometric MVC, the order
of which was randomized, through the 90° ROM. The loads for each participant were
determined, and then entered into the unilateral/isotonic protocol of the Biodex.
Participants also performed contractions at a minimum load that represented the
resistance of the dynamometer and the lowest possible additional load (1 N-m).
Participants performed two contractions at each load, one immediately after the other.
One minute rest was provided between each load. Subjects were instructed to contract as
explosively as possible on each attempt and to push through the load as fast as possible. A
practice trial at the minimum resistance was provided to ensure each participant
understood the instructions. Participants received visual feedback of contractile velocity
via a computer screen and strong verbal encouragement was provided.
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Data Analyses. Spike 2 computer software (version 5.14; Cambridge Electronic Design,
Cambridge, United Kingdom) permitted real-time display and inspection of data
channels. Torque production was measured in N-m, and velocity in degrees/second. Off
line, velocity was analyzed for peak values and converted to radians/sec. Power in Watts
was calculated by multiplying velocity (rads/sec) with torque (N-m).
2.1.3 Electromyographic Studies
EMG signals were acquired using "Aquire EMG", customized software for a
Neuroscan Comperio EMG system (Neurosoft, Sterling, VA). Intramuscular EMG signals
were detected using a standard concentric needle electrode (VIASYS Healthcare,
Madison, WI). During data collection, participants lay supine on a medical bed with their
back propped up with a pillow for comfort. The following muscle groups were studied in
all subjects: tibialis anterior, vastus lateralis, and biceps brachii. The surface of the skin
was cleansed with a pad saturated with 70% isopropyl alcohol prior to and following
insertion of the needle electrode. The concentric electrode was inserted about 0.5-1 cm
into the muscle tissue. Once the needle was inserted, the participant was instructed to
increase the isometric contraction force to a moderate level and the needle was positioned
to ensure minimal rise-times of the MUPs of the first few recruited motor units (ie crisp
EMG signals). Once adequate MUPs were detected, the participant was instructed to
isometrically contract so that the interference pattern was maintained at ~40 pps. The aim
of collecting MUPs at 40 pps was to account for the increased interference pattern
observed in myopathy seen at low contraction intensities. EMG signals at this frequency
were collected for 20 seconds. The participants were asked to maintain steady contraction
intensities throughout the 20-second contraction period. To aid participants in achieving a
constant contraction, visual and auditory feedback of the EMG signal was provided on a
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computer screen. If greater than three contractions were required to obtain data from the
minimum of 20 motor units per muscle, a second needle insertion was performed at a
different site. Needle EMG was collected with a sweep duration of lOms/div and high and
low frequency filters were set at 10 kHz and 10Hz, respectively.
Electromyography Signal Decomposition and Analysis. A series of algorithms
decomposed the needle-detected EMG signal into its constituent MUP trains. EMG signal
decomposition involved the detection, clustering of the detected MUPs, and the
supervised classification of the intramuscular signal. Pattern recognition algorithms
employed morphologic statistics such as peak-to-peak voltage, number of phases,
duration and slope to cluster individual MUPs into group responses of similar shape.
Using the clustering results, the supervised classification algorithm combined shape and
firing time statistics to calculate the certainty with which the individual MUP assignments
had been made. A prototypical MUP shape was then estimated for each MUP train. The
MUP shape was based on median-trimmed averaging of the data points over a 50-ms
interval centered on each MUP’s peak slope. Fifty-one selected MUPs were selected in
order to best estimate the MUP shape. Given the prototypical shape for each MUP, its
peak-to-peak amplitude (pV), duration (ms), and number of phases were automatically
determined9.
The MUP trains were then reviewed offline to determine their acceptability based
on predetermined criteria9. The interdischarge interval histogram was evaluated to ensure
a Gaussian-shaped main peak was displayed and a coefficient of variation of the
interdischarge interval of less than 0.3. MUP trains that did not meet these criteria were
excluded from further data analysis. For each acceptable MUP train, the associated MUP
waveforms was also visually investigated to ensure accurate placement of the onset,
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positive peak, negative peak, and end markers. Markers were manually repositioned if
needed.
2.1.4 Functional Performance Measures
Stair Climb: A standard 8-stair flight, with handrails on both sides, was used for
this measure. Participants were instructed to ascend the stairs as quickly and safely as
possible. Handrails were to be used if needed. A stopwatch measured time to the nearest
0.1 seconds. Time began at the initiation of the stair climb and stopped when both feet
were placed on the top step. Two trials were attempted and the average was recorded.
Gait Velocity: Participants were instructed to walk at a brisk pace for a distance of
10m. They followed a straight 10m path that was clearly marked on the floor and
completed trials with any walking aids normally used. A stopwatch was used to measure
time. Participants began walking 2 meters behind the ‘start’ line and finished 2 meters
past the ‘end’ line. This was done to avoid inclusion of the acceleration and deceleration
phases in the timed trial. Timing began when the participant crossed the ‘start’ line, and
stopped when they crossed the ‘finish’ line. The test was performed twice and the average
was recorded.
Chair Rise Time: a standard chair with arms was seated against a wall for support
and safety. Participants sat on the chair with their back against the chair back and with
both feet flat on the floor. Participants were instructed to stand fully upright then return to
the seated position as many times as possible during a 30 second period, timed with a
stopwatch. As the purpose of this task was to measure functional performance,
participants were instructed to perform the task in the manner that was most efficient for
them. A successful rise was considered the movement from sitting to fully standing, then
returning back to the seated position. A single test was performed due to participant
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fatigue. A qualitative assessment of the participant’s biomechanical strategy used to
complete the task was noted.
2.1.5 Magnetic Resonance Imaging
MRI of the thigh was performed at 3.0T with an 8-coil knee phased array. 3D
axial images were acquired with a proton density weighted IDEAL-SPGR chemical shift
imaging (FOV: 42-46x21-23 cm, slice thickness: 4 mm, matrix: 320x160x120, TR: 7.4
ms, echoes: 6, TE, 1.4, 2.1, 2.9, 3.6, 4.4, 5.1 ms, flip angle 5°, bandwidth: ± 142.86 kHz).
Image analysis was performed by subtracting the fat images from the water only images
produced by the IDEAL reconstruction. The quadriceps were segmented with a
combination of manual and region growing techniques using Osirix software. Muscle
volume was determined by analyzing the following region of image slices: the start slice
was determined as the first axial slice where the inferior aspect of the gluteus maximus
was no longer visible. Segmentation of axial slices continued distally and finished when
the superior aspect of the patella was first seen. Using these data, quadriceps volume was
calculated.
2.1.6 Statistical Analysis:
A Kolmogorov-Smirnov test was used to compare the distributions of MUP
parameters of the control and MD groups from the vastus lateralis muscle. A two-tailed
unpaired t-test was performed to compare the mean values of MUP parameters between
patient groups for all muscles investigated. The Pearson correlation coefficient was
applied to examine the correlation between MUP parameters and MVC, peak power, and
quadriceps muscle volume for patients with MD. To investigate which strength
measurement (MVC, peak power, power at 10% MVC, and quadriceps muscle volume)
best correlated with functional performance, a Pearson correlation coefficient was
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performed. Finally, two-tailed unpaired t-tests were performed to the compare mean
values of MVC, power, and functional performance between subject groups. Statistical
significance was determined at p<0.05. All data are presented as mean (+/- SD) range.
Data were analyzed using GraphPad Prism version 5.0c for Mac OS X (GraphPad
software, San Diego, California).

2.2 RESULTS
2.2.1 Subject Characteristics
Subject characteristics are presented in Table 2.1. Participants with muscular
dystrophy ranged in age from 20-59 years (average 41 ± 13 years, 12 males: 3 females).
Four participants, with an average age of 45 years (SD=17 years), had previously
determined diagnoses of FSHD. Patients with FSHD reported they had experienced
symptoms of their MD for the previous 4-25 years (mean 13 years). The MD participant
group was also comprised of 6 and 5 patients previously diagnosed with LGMD and
BMD, respectively. Duration of disease manifestation ranged from 2-16 years (average 7
years) for patients of LGMD and ranged from 7-36 years (average 20 years) for patients
with BMD.
Data collected from participants with muscular dystrophy were analyzed
collectively as a group, and were also divided into ‘less severely’ and ‘more severely’
affected subgroups. Subgroup differentiation was determined by quadriceps MVC
strength. Seven patients, 6 males and 1 female, with muscular dystrophy (FSHD: 4,
BMD: 1, LGMD: 2) whose MVC strength was 100 N-m or greater, were characterized as
having ‘less severe’ MD. The average disease duration of this group was reported as
being 10 years (± 9 years) with a range of 2-25 years. Eight patients, 6 males and 2
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females, (FSHD: 0, BMD: 4, LGMD: 4) with an MVC less than 100 N-m were
characterized as having ‘more severe’ MD. The average disease duration of this group
was reported as being 15 years (± 13 years) with a range of 4-36 years.
2.2.2 Strength And Power Measurements;
Isometric strength: The quadriceps muscle group of patients with MD was significantly
weaker, as determined by isometric MVC torque, than those of the control group
(p<0.01). However, quadriceps muscle strength for the LS group was the same as that
observed in the control subjects. MVC torque was significantly reduced in the MS group
compared with the LS group (p<0.0001). Mean MVC torque values are reported in Table
2 .2 .
Isotonic Power: One patient with MD was unable to complete the power testing as both
legs demonstrated less than antigravity strength and thus, this participant was unable to
perform the dynamic contractions through the required 90° ROM. Patients with MD
generated significantly less power than control subjects at all of the normalized
submaximal loads tested (p<0.05) (Figure 2.1). The reduction in power between the two
groups ranged from 28% at 1 N-m to 61% at 50% MVC. Power was significantly reduced
in the MS group compared to both the control (p<0.01) and LS groups (p<0.01) at all
normalized loads (Figure 2.1). Power was reduced at all normalized loads for the LS
group compared with control subjects, however this reduction was not significant. Peak
power was achieved at 40% MVC for the MD and LS groups, and at 50% MVC for the
control and MS groups (Figure 2.1).
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2.2.3 Quadriceps Muscle Volume
Mean values for quadriceps muscle volume (QMV) for control, MD, LS, and MS
groups are presented in Table 2.2. QMV was obtained for twelve patients with MD and
for six controls. There was a significant reduction in muscle volume in the MD group
compared with controls (p<0.05). Of the twelve patients with MD whose muscle volume
was measured, seven were considered LS and five were considered MS. Participants in
the MS group had significantly reduced muscle volume compared to both the control
group (p<0.01) and to the participants in the LS group (p<0.01). Quadriceps muscle
volume of the LS group was the same as QMV of the control group. Refer to Appendix C
for MRI of a healthy and a MD quadriceps muscle group.
2.2.4 Functional Performance Measures
An overview of results from the chair rise, gait velocity, and stair climb for the
control, MD, LS and MS groups are included in Table 2.2. Again, one patient with MD
was too weak to perform these tasks and therefore unable to complete the functional
performance section of the protocol. Control subjects performed significantly better than
patients with MD on the chair rise (p<0.01) and the 10m walk (p<0.05). Although
patients with MD took longer to climb 8 stairs compared with control subjects, this
difference was not significant (p=0.0506). A significant difference between the LS group
and the MS group was only observed in the chair rise task (p<0.01).
2.2.5 Correlations between Strength. Power, and Functional Performance
In the MD patient group, MVC torque demonstrated the strongest correlation to
functional ability (Table 2.3). While power at 10% of MVC significantly correlated with
functional ability on all three functional tasks (SC: r= -0.73, p<0.05; CR: r=0.61, p<0.05;
GV: r= -0.69, p<0.05), peak power only correlated significantly with the stair climb
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(r=-0.73, p<0.05) and gait velocity tasks (r= -0.66, p<0.05) (Table 2.3). Although a
significant correlation existed between QMV and performance on the stair climb task
(r=-0.73, p<0.05), there was no significant correlation between QMV and performance on
the chair rise or gait velocity tasks. There was no correlation among any of the strength
measurements and performance on functional tasks in the control group.
In summary, MVC seems to predict overall functional performance just as
strongly as isotonic power. This finding may be clinically useful as determining isometric
strength with a dynamometer is less time consuming and is a less fatiguing protocol then
when determining power.
2.2.6 Electrophysiological Measures
The frequency distributions of needle-detected MUP parameters collected from
the vastus lateralis muscle group are illustrated in Figures 2.2-2.7. The MUP amplitude
distributions, collected from the vastus lateralis, revealed MUPs from myopathic muscle
were smaller than the control group (D=0.1334, p<0.05) (Figure 2.2). Also, the MUP
duration (D=0.2211, p<0.0001), area (D=0.2642, p<0.0001), and area-to-amplitude ratio
(D=0.2527, p<0.0001) frequency distributions for the MD group were shifted to the left,
compared to the control group (Figure 2.3-2.5). Thus, MUPs collected from myopathic
muscle tend to be shorter in amplitude and duration, smaller in area, and thinner than
MUPs collected from healthy muscle. A comparison of the distribution of MUP phases
revealed that they are similar between controls and myopathic muscle (D=0.0808,
p=0.432) (Figure 2.6). The distribution of MUP turns is shifted right compared with
controls (D=0.1878, p<0.001) indicating a greater number of turns in the vastus lateralis
of patients with MD (Figure 2.7).
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The mean MUP amplitude (peak-to-peak amplitude), collected from the vastus
lateralis and tibialis anterior muscle groups, were not significantly different between the
MD and control groups. However, the MUP amplitude in the MD group collected from
the biceps brachii was greater than controls (p<0.01, Table 2.4). The mean duration of
needle-detected MUPs collected from the vastus lateralis and the biceps brachii were
significantly shorter (pO.OOOl and p<0.01 respectively, Table 2.4) in patients with MD
compared with controls. Mean vastus lateralis MUP area was significantly smaller in the
MD patients compared with control subjects (pO.OOOl, Table 2.4), but no significant
difference was observed in the MUP area collected from the other muscle groups. Needledetected MUP AAR was different amoung groups for all three muscles sampled, with
smaller values observed for the patients with MD than control subjects (VL: pO.OOOl,
TA: pO.05, BB: pO.OOOl, Table 2.4). While the mean number of phases in the vastus
lateralis, tibialis anterior, and biceps brachii muscle groups between patients with MD and
control subjects were the same, the mean number of turns was significantly greater in all
three muscle in patients with MD compared with control participants (VL: pO.OOOl, TA:
pO.Ol, BB: pO.OOOl, Table 2.4).
In the vastus lateralis, mean MUP duration, area, and area-to-amplitude ratio were
significantly less in the MS group compared with the LS group (pO.OOOl for all
parameters, Table 2.5). Mean MUP peak-to-peak amplitude and the number of phases and
turns in the vastus lateralis were the same between patients with MS and LS muscular
dystrophy. Number of turns was the only MUP parameter to be significantly different
between MS and LS patients in the tibialis anterior muscle group (pO.Ol, Table 2.5).
Finally, in the biceps brachii, the number of phases, as well as number of turns, were
significantly greater in the MS group (pO.OOOl for both parameters, Table 2.5).

The parameters of the needle-detected MUPs collected from the vastus lateralis
were correlated with measures of strength to determine if a relationship existed. It was
observed that MUP duration was significantly correlated with MVC (r=0.60, p<0.05),
peak power (r=0.675, p<0.05), and quadriceps muscle volume (r=0.585, p<0.05) in
patients with MD (Table 2.6). In addition, the number of turns correlated significantly
with QMV in patients with MD (r= -0.81, p<0.05). No other correlation between MUP
parameter and MVC, peak power, or quadriceps muscle volume was significant (Table
2.6). There was no significant correlation observed between any of the analyzed MUP
parameters and MVC or peak power for control subjects. Control values for QMV were
obtained from a different control population than those who completed the
electrophysiological and muscle function testing. Therefore, a relationship could not be
determined.

Table 2.1 Subject Characteristics

Age (yrs.)

Sex
(male:female)

Weight (kg)

Height (cm)

Duration of
Symptoms (yrs.)

More/less
severe (±/-)

FSHD
(n=4)

45 ± 16
(20-56)

3:1

73.5 ± 19.1
(58.5-101)

173.7 ± 13.2
(158-187)

13 ± 11
(4-25)

0/4

LGMD
(n=6)

36 ± 10
(21-46)

4:2

71.6 ± 16.9
(54-98.5)

170.8 ±7.7
(159-179)

7± 5
(2-16)

4/2

Becker’s MD
(n=5)

43 ± 13
(29-59)

5:0

71.1 ±7.03
(63-79.5)

168.8 ±3.9
(165-175)

20 ± 14
(7-36)

4/1

Controls
(n=7)

35 ± 12
(23-57)

5:2

73.3 ± 7.2
(64.6-84)

179.1 ±8.2
(172-190.5)

N/A

N/A

Data presented as means ± SD. Data in parentheses indicate range. FSHD, fascioscapulohumeral muscular dystrophy; LGMD.
Limb girdle muscular dystrophy; MD, muscular dystrophy.

Table 2.2 Muscle properties and functional performance

MVC (N-m)

Controls
(n=7)

202.5 ± 76.4
(125.6-328.8)

Peak Power
(Watts)

Stair Climb

449.7 ± 174.7
(249.4-710.9)

3.9 ±0.3
(3.2-4.1)

(s)

Chair Rise
(number of
reps)
21.5 ±4.0
(17-28)

10m walk task

(s)
5.1 ±0.6
(4.23-5.8)

Quadriceps
Muscle Volume
(cm3)
1165.4 ±284.2
(835.7-1632.6)
(n=6)
758.4 ±382.5 *
(165.2-1299.8)
(n=12)
984.9 ±313.4
(578.0-1299.7)
(n=7)

7.0 ± 1.8 *
8.1 ±5.3
11.5 ±6.5 *
Muscular
98.2 ± 74.7 *
180.8 ± 172.1*
(4.16-9.72)
(2.78-21.4)
(2.5-26)
(5.21-472.6)
Dystrophy
(16.9-225.0)
(n=14) '
6.2 ± 1.8
14.5 ± 6.0 *
157.9 ±58.2
318.9 ± 134.7
4.7 ± 1.7
Less Severe
(4.16-9.72)
(5.5-26)
(154.4-472.6)
(2.8-7.6)
Muscular
(99.5-225.0)
Dystrophy
(n=7)
7.8 ± 1.4*
441.4 ± 198.8
9.0 ±6.5 *
11.5 ±5.5 *+
38.4 ±20.9 *t
42.5 ± 38.2 *t
More Severe
*t
(6.4-9.5)
(4.12-21.4)
(2.5-21)
Muscular
(5.2-106.5)
(16.9-71.7)
Dystrophy
(165.2-692.4)
(n=7)
________________________ (n=5)
Values expressed as means ± SD. Data in parentheses indicate range. * indicates significant difference than controls,
+ indicates significant difference from Less Severe muscular dystrophy group. MVC, maximum voluntary contraction.
One patient with MD was unable to complete the power and functional tasks as they demonstrated antigravity strength. Their
MVC was below 100 N-m and thus, were apart of the more severe muscular dystrophy subgroup.

Table 2.3 Strength measurements correlated to functional tasks in patients with muscular dystrophy

Stair Climb

Chair Rise

Gait Velocity

Power at 10% MVC

r = -0.73
p<0.05

r = 0.61
p<0.05

r = -0.69
p<0.05

Peak Power

r = -0.73
p<0.05

r =0.53
ns

r = -0.66
p<0.05

MVC

r = -0.74
p<0.05

r = 0.62
p<0.05

r = -0.69
p<0.05

Quadriceps Muscle Volume

r = -0.73
p<0.05

r = 0.37
ns

r =-0.58
ns

MVC, maximum voluntary contraction; ns, not significant.

Table 2.4 Electrophysiological data for control and MD subject groups

Vastus Lateralis___________________Tibialis Anterior__________________Biceps Brachii
MD
MD
Control
Control
MD
Control
P-P
Amplitude
(pV)
Duration
(ms)

703 ± 572
(122-3458)

595 ± 490
(93-2875)

464 ± 391
(124-3726)

537 ± 442
(87-4035)

338± 169
(112-1210)

415 ± 351*
(84-3361)

12.0 ±3.9
(3.0-25.2)

10.5 ± 3.6*
(1.6-24.4)

10.9 ±3.5
(3.2-24.7)

11.4 ± 3.9
(3.4-32.3)

9.9 ±3.2
(4.1-23.3)

8.9 ±2.9*
(3.2-19.9)

Area
(pVms)

1199.3 ±837.3
(70.5-4482.5)

882.8 ±815.0*
(39.2-6146.6)

750.4 ± 540.2
(94.2-4564.4)

763.0 ±504.8
(77.6-4758.1)

572.6 ±317.9
(109.0-1835.5)

514.2 ±419.6
(36.1-3736.4)

AAR (ms)

1.80 ±0.52
(0.53-3.89)

1.47 ±0.53 *
(0.30-3.05)

1.72 ±0.61
(0.50-3.40)

1.58 ±0.62*
(0.43-5.90)

1.7 ±0.52
(0.69-4.38)

1.30 ±0.40*
(0.27-3.90)

Phases

3± 1
(0-6)
3± 1
(1-9)

3± 1
(0-7)
4± 2 *
(1 -11)

3± 1
(1-9)
4±2
(1-11)

3± 1
(0-8)
5 ±3*
(1-18)

3± 1
(1-5)
3± 1
(1-5)

3± 1
(0-8)
4±2 *
(1-13)

Turns

Values expressed as mean ± SD. Data in parentheses indicate range. * indicates value is significantly different than control values
P-P Amplitude, peak-peak amplitude; AAR, area-to-amplitude ratio (thickness)

Table 2.5 Electrophysiological data for ‘less severe’ and ‘more severe’ subject groups

Vastus Lateralis
Less Severe
More Severe
P-P
Amplitude
(uV)
Duration
(ms)
Area
(uVms)
AAR (ms)

681 ±681
(93-2875)

566 ± 693
(104-6434)

Tibialis Anterior
Less Severe
More severe
570 ±383
(104-2556)

511 ±484
(87-4035)

Biceps Brachii
Less Severe
More Severe
386 ± 296
(102-2044)

436 ±387
(84-3361)

8.9 ±3.2
11.7 ±4.0
8.9 ±2.6
8.8 ± 3.0*
11.1 ±3.8
(3.2-19.5)
(3.8-19.9)
(3.4-20.5)
(4.03-32.3)
(1.6-17.5)
501.2 ±447.2
524.1 ±398.0
729.2 ±531.9
660.1 ±540.8 *
805.6 ± 466.5
(75.2-3736.4)
(36.1-2293.8)
(77.6-4758.1)
(98.1-2860.6)
(39.2-3222.7)
1.33 ±0.42
1.30 ±0.50
1.62 ±0.68
1.55 ±0.52
1.29 ±0.53 *
(0.26-3.9)
(0.43-5.92)
(0.36-3.50)
(0.48-3.80)
(0.31-2.83)
2± 1
3± 1*
3± 1
3± 1
Phases
3± 1
(0-8)
(0-6)
(0-7)
(0-7)
(1-8)
4± 2 *
3± 1
4± 2
5 ±3*
Turns
4±2
(1-13)
d-8)
(1-12)
(1-18)
0-11)
_____ Í H ! ) _____
Values expressed as mean ± SD. Data in parentheses indicate range * indicates that value is significantly different than less severe MD
values . P-P Amplitude, peak-peak volume; AAR, area-to-amplitude ratio (thickness)
12.1 ±3.4
(4.1-24.4)
1112.8 ±973.3
(133.9-6146.6)
1.66 ±0.44
(0.40-3.05)
3± 1
(1-6)
4±2

Table 2.6 Vastus lateralis MUP parameters correlated to muscle characteristics in patients with muscular dystrophy

Peak Power
Muscle Volume
MVC
r= -0.47
r=0.12
r= 0.12
ns
ns
ns
i=0.59
r=0.68
r=0.60
Duration (ms)
p<0.05
p<0.05
p<0.05
r= -0.24
r= 0.43
r=0.38
Area (pVms)
ns
ns
ns
r=0.40
i=0.50
r= 0.42
AAR (ms)
ns
ns
ns
r= -0.53
r=0.02
r=-0.12
Phases
ns
ns
ns
r= -0.81
r=-0.27
r=-0.29
Turns
p<0.05
ns
ns
P-P Amplitude, peak-to-peak amplitude; AAR, area-to-amplitude ratio; MVC, maximum voluntary contraction; ns, not
significant.
EMG Parameter
P-P Amplitude (pV)

VO

Control
Less Severe
MD
More Severe

Figure 2.1

Comparison of isotonic power at INm and all normalized submaximal loads. * indicates significant difference
from controls. _L indicates a significant difference from ‘Less Severe’ group.
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Figure 2.7 Distribution o f MUP turns for both control
subjects (solid bars) and MD patients (open bars).
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2.3 DISCUSSION
2.3.1 Major Findings
The purpose of the present study was to investigate whether MUP parameters,
collected using DQEMG, reflect the clinical presentation of patients with LGMD, FSHD,
and BMD. To date, no investigation has determined if a relationship exists between
objective clinical measures and EMG in patients with MD. Furthermore, we were
interested whether isotonic power was better able to predict the functional ability of
patients with MD than isometric strength. In addition, we hypothesized that power
generated at a lower percentage of maximum load (10% of MVC) would correlate to
functional ability more strongly than peak power. To our knowledge, no investigation has
examined isotonic power in the assessment of functional ability in a myopathic
population. Our results demonstrate that: 1) the functional ability of patients with MD
was compromised compared to controls in the chair rise and gait velocity tasks; 2) the
more severe MD group differed in their functional ability to a greater extent than the less
severe MD group when compared with controls; 3) patients with MD demonstrated a
significant loss of power; 4) power at 10% of MVC correlated more strongly with
functional ability than peak power, however, 5) MVC better predicted functional
performance than peak power, power at 10% of MVC, and QMV 6) Needle detected
EMG reflected the progressive nature of MD and 7) the EMG feature, MUP duration,
correlated significantly to measures of strength.
2.3.2 Clinical Aspects
Results of this study indicate that patients with MD performed worse on the
functional tasks compared to controls. Their performance on the chair rise and gait
velocity tasks was significantly poorer than that of the control group. Climbing stairs,

51

rising from a chair, and gait velocity were selected to assess functional ability, as they are
commonly encountered activities in daily living. As well, successful completion of these
activities largely requires the activation of muscle groups that are primarily affected in
FSHD, LGMD, and BMD. Interestingly, patients with ‘less severe’ MD performed the
stair climb and gait velocity tasks similar to the control participants, and functional ability
only differed significantly in the chair rise task. The ‘more severe’ MD group on the other
hand, demonstrated compromised functional ability in all three performance tasks
compared with controls. Our finding that patients with MD maintain their ability to
perform functional tasks over a period of years before experiencing a significant decline
in function is supported in the literature3,1. It is suggested that a pattern of compensatory
mechanisms are used by patients in order to achieve functional goals, even while their
muscle strength deteriorates1. In the current study, it was observed that patients with MD
employed various biomechanical strategies in order to efficiently complete each task.
Patients tended to complete the tasks in a manner that utilized less affected muscle
groups. For example, during the chair rise task patients commonly used their arms to lift
themselves out of the chair. Thus, the LS group were able to perform activities of daily
living functionally the same as control subjects, but used different mechanical strategies
to in order to complete the activities. As MD progresses and involves more muscle
groups, patients eventually are unable to employ these strategies. At which point
functional ability greatly diminishes. This is reflected in the MS group’s functional ability
differing significantly from controls for all tasks.
This study also revealed that patients with MD demonstrate a significant loss of
power. While patients with MD generated less absolute power at all normalized loads, the
percentage of MVC at which peak power was achieved did not decrease in accordance
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with MD severity. Peak power was achieved at 50% MVC load in both the controls and
the MS groups, and at 40% MVC load in the LS and MD groups. While McNeil et al.
reported that men aged 19-33 years also achieved peak power at 50% of MVC, albeit in
the dorsiflexor muscle group, they also reported that the load at which peak power was
achieved decreased progressively with increasing age14. This group attributed a decrease
in the velocity of movement, rather than absolute strength level and muscle mass, as the
predominant factor in the loss of power between the young and old groups. In the present
study, results from the MVC and MRI indicate that our patient population had significant
decrements in both absolute strength and quadriceps muscle mass. As our patient group
maintained peak power at a similar percentage of MVC load to the control group, it could
be speculated that the reduction in power output observed in patients with MD is
primarily attributed to the loss of muscle mass and decrement in absolute force
production, and to a lesser degree to a decrease in contraction velocity.
In accordance with the literature8, our study found that power generated at lower
percentages of maximum force (10% of MVC) correlated more strongly with functional
ability than peak power output. This is not surprising as the tasks performed; stair climb,
chair rise, and gait velocity are executed by generating low force and high shortening
velocity movements. Contrary to our hypothesis however, the results indicate that
absolute isometric force production, determined by MVC, correlated more strongly with
functional ability than power output did. It was predicted that power would better predict
functional performance since the functional tasks are both velocity and strength
dependent. As well, it is well documented in the literature that in aging populations power
consistently demonstrates a stronger relationship to functional ability than strength ’ ’ ’ .
As previously mentioned in this discussion, deficits in power of the dosirflexor muscle
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group in old adults (65 years old) are largely attributed to decreased contraction velocity,
and to a lesser extent due to decreased muscle strength14. Results from our study indicate
that muscle mass and muscle strength are both decreased significantly in our patient
population. Therefore, for patients with MD, decrements in power output may be
primarily attributed to the defects in strength, rather than to the velocity of contraction.
This would explain why absolute muscle force, or MVC, represented limitations in
function just as well as power measures, which incorporates both force and velocity
parameters. Our finding that MVC best predicts functional ability in patients with MD
may have clinical implications as isometric strength can easily be assessed using a
dynamometer.
Lastly, quadriceps muscle volume was correlated significantly only to the stair climb
functional task. A lack of correlation with the other tasks may be due to the utilization of
alternative mechanical strategies to perform the tasks. Therefore, there may have been
limited involvement of the quadriceps muscle group during task completion.
2.3.3 Electrophysiological Studies
In the present study, DQEMG detected MUPs recorded from the muscles of
patients with MD were characteristic of myopathy, as reported in the literature13,7,11.
Vastus lateralis, tibialis anterior, and biceps brachii MUPs were short in duration (except
TA), ‘thin’, and more complex compared with control MUPs. In addition, vastus lateralis
MUPs were smaller in area and biceps brachii MUPs had smaller amplitude. MUP
morphology reflects the underlying physiology of the MU from which conclusions
regarding the pathological changes associated with the dystrophic process can be
elucidated. MUP duration reflects the size of the MU4. This parameter is thought to be the
most sensitive feature of abnormality ’ . The MU territory decreases in MD as muscle
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fibers degenerate, become necrotic, and are subsequently replaced by fat and connective
tissue. This also causes a decrease in the number of muscle fibers per unit of cross
sectional area, or decreased fiber density, as compared with normal muscle4. It is
suspected that the general thinning of the MU by the diffuse distribution and random loss
of muscle fibers is the most likely cause of the decreased MUP duration in MD. As
muscle fibers degenerate, the single muscle fiber potentials, which comprise the initial
and terminal portions of the MUP, become absent. Thus, the temporal dispersion of the
remaining fibers is diminished, resulting in a shortened duration4,7.
In the present study, the MUP amplitude of the biceps brachii was increased
compared with control values. Although it is more commonly reported that MUP
amplitude is reduced in myopathies11,7, there remains discussion in the literature
regarding the possible pathology associated with increased amplitude in MD. It is
suggested that this phenomenon results from the presence of hypertrophic fibers formed
by regenerative processes in the intermediate stages of the disorder4. It is well established
that amplitude of the concentric needle MUP is highly dependent on the position of the
needle detection surface relative to the muscle fibers of a given MU, and reflects only the
contribution of a small number of muscle fibers closest to the tip16. Thus, it is reasonable
that an increase in MUP amplitude may be produced by a single, hypertrophic muscle
fiber close to the recording electrode.
A decrease in MUP area was observed only in the vastus lateralis muscle group in
our study. As MUP area depends on the number of muscle fibers within a large portion of
the MU territory, it would be expected to decrease in myopathy as muscle fibers become
lost during the degeneration process17.
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Measurements of MUP amplitude and area are both greatly influenced by needle
placement and thus, may not accurately reflect the pathophysiological changes of
diseased muscle. MUP AAR quantifies MUP thickness. This feature has been proposed to
be more clinically useful than MUP amplitude and area as it is less sensitive to electrode
position. By calculating the ratio, the effect of amplitude is partially offset, and the
decrease in area is more evident16. This could explain why in the present study AAR was
significantly decreased in all muscles investigated, compared with controls, while area
was only significantly reduced in the vastus lateralis. Furthermore, AAR was reduced in
the biceps brachii even though the mean MUP amplitude in this muscle group was
significantly increased compared with controls. The results of this study lend further
support that AAR may better represent overall pathological changes in myopathic
muscles than MUP amplitude and area alone.
Finally, although mean number of phases was not different between controls and
patients with MD in the present study, we did observe a significant increase in the number
of turns in all muscle groups. Increased MUP complexity is due to variation in muscle
fiber diameter and uneven fiber dispersion, which causes less synchronous muscle fiber
firing. Buchthal et al. measured muscle fiber diameters in muscle biopsies in patients with
MD and found that due to both hypertrophic and atrophic muscle fibers, the range of
diameters was twice that of normal4. Furthermore, using a simulated myopathic model,
Stalberg & Karlsson found that increased MUP complexity in myopathic muscle was
indeed the result of large variation in muscle fiber diameter21. Changes in fiber density,
resulting from muscle fiber loss, are also speculated to cause an increased incidence of
polyphasic potentials in myopathies. This occurs as the temporally dispersed discharges
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of the surviving fibers in the MU near the electrode appear as separate spikes, rather than
as the smooth triphasic MUP observed in normal muscle4.
For FSHD, LGMD, and BMD, weakness generally manifests first in the proximal
muscle groups, and then may progress distally. The EMG results of this study reflect this
progression of disease involvement. The vastus lateralis, apart of the quadriceps muscle
group, which is initially involved in LGMD and BMD, shows the most significant and
extensive changes in MUP morphology compared with controls. The biceps brachii, also
a proximal muscle group and often one of the first muscles to manifest signs of weakness
in FSHD, shows similar changes in MUP morphology as the vastus lateralis. In the
tibialis anterior, only MUP AAR and the number of turns differed between the MD and
control groups. Buchthal reported that MUP duration is more pronounced in muscles with
more advanced weakness and furthermore, that shortened MUP duration is more apt to be
found in proximal than distal muscles7. We reported a similar finding, as MUP duration
was significantly decreased in the two proximal muscle groups, while no difference in
MUP duration between MD and control groups was observed in the tibialis anterior. Our
EMG findings are further supported in the literature as it is reported that a simulated
increase in muscle fiber variation resulted in more complex MUPs, as the number of
phases and turns increased, while only minor changes in amplitude and duration
parameters were observed21. It was not until there was loss of muscle fibers and abnormal
distribution of fiber diameters, which reflected disease progression, that area and
duration, and to a lesser degree amplitude decreased21. Therefore, our results suggest that
in the tibialis anterior there is increased variation in fiber diameters while relatively few
fibers have been lost to the degenerative processes. This reflects the dystrophic process at
a relatively earlier stage. The MUP parameters from the vastus lateralis and the biceps
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brachii muscle groups in our MD patient group however, suggest more advanced
pathological changes as MU territory and fiber density have been reduced, as well as the
presence of increased variation in fiber diameter.
Similar changes in MUP morphology reflecting disease involvement were
observed between the ‘less severe’ and ‘more severe’ muscular dystrophy patient groups.
Group differentiation was determined by quadriceps muscle strength. Therefore, it is not
surprising that the changes observed in the MUP parameters of the vastus lateralis
between the LS and MS group were most indicative of a more severe dystrophic process
compared to the other muscle groups. MUP area, duration, and AAR were all
significantly reduced in the MS group compared with the LS group. Pathologically, this
indicates that muscle fiber degeneration has occurred to a greater extent, leading to a
greater decrease in MU territory and fiber density in the MS group than the LS group in
the vastus lateralis. Surprisingly, there was no difference in complexity between LS and
MS groups in the vastus lateralis. This might suggest there is an upper limit to the extent
of variation in fiber diameter, at which point the dystrophic process progresses and
substantial fiber loss occurs. MUP complexity was the only parameter that was
significantly different between the MS and LS groups in the biceps brachii and tibialis
anterior groups. Pathologically, this suggests that for these two muscles, the MS group
has increased variation in muscle fiber diameter. However, as MUP duration did not
differ between the patient groups, the extent of muscle degeneration must be similar.
As EMG provides information pertaining to the architecture of the MU and the
underlying pathological changes in muscle associated with myopathy, it is not surprising
our results indicated that MUP duration correlated with measures of strength. In the
vastus lateralis, MUP duration correlated with muscle force and peak power output. As
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previously discussed, MUP duration reflects the MU size. Therefore, a decrease in MUP
duration corresponds to a decreased fiber density as a result of the random loss of muscle
fibers. The loss in muscle fibers then manifests functionally as a decline in strength. This
is supported by the results of MRI, which also correlated with MUP duration. As muscle
volume decreases, there is a corresponding decrease in MUP duration.

2.4 SUMMARY AND CONCLUSIONS
Patients with MD had reduced quadriceps strength, power, muscle volume and
functional ability compared with our healthy control group. Power generated at lower
percentages of maximal force better predicted patients’ performance on the functional
tasks than peak power. However, the results indicate MVC correlated to functional
performance just as strongly as power (10% MVC) did. Therefore, assessing isometric
quadriceps strength with a dynamometer may provide clinically useful information
related to the functional ability of an individual with MD.
The present study demonstrated that DQEMG was able to indicate the extent of
disease involvement in myopathic muscles. Muscles that were involved later in the
disease process, such as the tibialis anterior, only differed from controls in MUP AAR
and number of turns. Proximal muscle groups, such as the vastus lateralis and biceps
brachii are typically involved in the initial stages of the disease process and were
therefore more affected. These muscles also showed decreased MUP AAR and increased
number of turns, but in addition MUP duration was also significantly reduced. Therefore,
the presence of shortened MUPs may indicate an advanced disease process, and reflect
that there are an increased number of fibers lost to degeneration and necrosis. In addition,
it is not surprising that MUP duration correlated with the clinical features investigated in
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this study. EMG provides information of the architecture of the MU that explains the
underlying pathophysiology of the dystrophic disease process. The associated changes in
the MU then manifests clinically as decreases in strength and atrophy.

2.5 LIMITATIONS
A potential limitation in this study was the limited number of patients that were
tested in the ‘less severe’ and ‘more severe’ muscular dystrophy groups. Changes in EMG
may have been more evident with a greater sample size. A larger sample size was not
collected due to the difficulty of recruiting patients with these particular diagnoses in a
restricted period of time. Also, the control sample size was half that of the participants
with MD. Differences between participant groups might have been clearer by increasing
the number of control subjects.
Other limitations in this study were associated with the functional testing. A
standard stopwatch was used to assess performance on the functional tasks. Due to the
nature of the equipment, there was potential for assessor error while measuring time. In
addition, performance on these timed tests can be affected by the patient’s mood, level of
motivation, and ability to cooperate. Furthermore, while each task was explained to the
participants using the same instructions, interpretation of these instructions may have
varied between participants and thus all individuals may not have competed the tasks in a
manner representing their absolute ability.
Although subjects were instructed to maintain the EMG interference pattern at
~40 pps, this was at times difficult due to the inherent nature of the myopathy. Patients in
more intermediate stages of the disease process had large interference patterns at a
relatively low contraction force, while participants who were very progressed in their
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disease could only recruit a few motor units even while contracting at maximum
intensities. Since there was variability in the contraction intensities and in the interference
patterns between participants, motor units of different thresholds may have been
recruited. Therefore, this could be a limitation in the comparison of EMG between
groups.

2 .6

FUTURE DIRECTIONS
In future investigations, MRI could be employed to normalize MVC torque and

peak power to quadriceps volume. This will allow us to investigate the specific strength
and specific power of patients with MD to compare with controls. Results of those studies
could help elucidate whether loss of muscle mass is indeed primarily accountable for the
decrement in power and strength observed in the present study. This information could
also help explain why the results of this study differ from the literature, as decreased
power may be caused by different physiologic mechanisms in myopathic and aging
populations.
Also, it would be interesting to investigate whether EMG findings correlate to
MRI. EMG provides insight into the physiological function of muscle, where assumptions
regarding the anatomy can be made only indirectly. MRI provides information from the
opposite orientation where anatomic integrity is primarily investigated and assumptions
regarding muscle physiology are made. A study investigating whether EMG and MRI
correlate would be able to determine if the physiological and anatomical information of
the neuromuscular system are complementary. We were unable to investigate this
question at the present time as not all patients completed the MRI portion of the protocol
due to safety and scheduling reasons.
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